We sometimes hear about diminishing returns in cancer research and development in the big pharmaceutical companies. They tell us, traditional drug discovery techniques have picked most of the low-hanging fruit in the field. Cancer cells are tricky devils, able to quickly mutate resistance to our best available therapies.
Biotech a drug discovery engine
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.
View the original article here: Biotech a drug discovery engine
The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.
Outbreak Daily Digest
Known by some as the "Environmental Worrying Group," EWG lobbies ...
- Are women superior to men? Research suggests most of us are more likely to believe that sex differences favor females
- Beepocalypse Myth Handbook: Assessing claims of pollinator collapse
- Athletic boost? A year after starting hormone treatments, transgender women still have an advantage over cisgender peers
- Podcast: How do mRNA vaccines work and why were they developed so fast?
- Gattaca or life-saving? Can we—should we—use CRISPR to edit human embryos, sperm or eggs to cure diseases?